Go Pro
NASDAQ:BTCY

Biotricity (BTCY) Stock Price, News & Analysis

Biotricity logo
$0.10 -0.01 (-4.55%)
As of 08/7/2026 03:52 PM Eastern

About Biotricity Stock (NASDAQ:BTCY)

Advanced

Key Stats

Today's Range
$0.11
$0.11
50-Day Range
$0.10
$0.14
52-Week Range
$0.09
$0.75
Volume
1,999 shs
Average Volume
56,355 shs
Market Capitalization
$2.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Biotricity, Inc. (NASDAQ:BTCY) is a digital health company specializing in remote patient monitoring solutions across cardiovascular and chronic disease management. The firm develops and commercializes a patented wearable biosensor platform designed to capture continuous physiological data, including electrocardiogram (ECG) readings and heart rate variability. This integrated system combines lightweight, adhesive biosensors with cloud-based analytics and clinician-facing software to support early detection of cardiac arrhythmias and facilitate telehealth care delivery.

The company’s flagship offering, the Bioflux™ platform, comprises a small, single-use wearable device that transmits real-time data to a secure portal, where advanced algorithms analyze cardiac patterns and generate clinician alerts. Complementing the hardware are subscription-based services—such as Bioflux™ Rx—through which Biotricity provides end-to-end monitoring programs under a prescription model. These programs enable cardiologists, primary care physicians, and remote monitoring centers to review patient data remotely, optimize treatment plans and enhance patient engagement without the need for in-office visits.

Founded in 2015 and headquartered in Menlo Park, California, Biotricity serves healthcare providers and payors throughout the United States, with emerging international partnerships aimed at expanding telemedicine adoption. Under the leadership of Founder and Chief Executive Officer Amir Kalali, the company has secured regulatory clearances for multiple product lines and continues to invest in research and development to broaden its digital health ecosystem. Biotricity’s solutions target efficient, patient-centric care by leveraging real-world data and scalable technology to address growing demands for remote monitoring in modern healthcare.

AI Generated. May Contain Errors.

Receive BTCY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biotricity and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BTCY Stock News Headlines

Biotricity Q3 2026 Earnings Call: Complete Transcript
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.tc pixel
Biotricity, Inc. (BTCY) Q3 2026 Earnings Call Transcript
Biotricity Inc.
See More Headlines

BTCY Stock Analysis - Frequently Asked Questions

Biotricity's stock was trading at $0.30 at the beginning of 2026. Since then, BTCY shares have decreased by 65.0% and is now trading at $0.1050.

Biotricity, Inc. (NASDAQ:BTCY) announced its earnings results on Wednesday, February, 11th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.04. The company earned $3.99 million during the quarter.
Read the conference call transcript
.

Shares of Biotricity reverse split on Monday, July 3rd 2023.The 1-6 reverse split was announced on Monday, July 3rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 3rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

Biotricity (BTCY) raised $15 million in an initial public offering on Thursday, August 26th 2021. The company issued 5,000,000 shares at a price of $3.00 per share. H.C. Wainwright & Co. acted as the underwriter for the IPO.

Shares of BTCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Biotricity investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Broadcom (AVGO), Micron Technology (MU) and Bank of America (BAC).

Company Calendar

Last Earnings
2/11/2026
Today
8/09/2026
Next Earnings (Estimated)
8/13/2026
Fiscal Year End
3/31/2027

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Equipment
Current Symbol
NASDAQ:BTCY
Previous Symbol
OTCMKTS:BTCY
CIK
1630113
Fax
N/A
Employees
40
Year Founded
2014

Profitability

EPS (Trailing Twelve Months)
($0.12)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$14.09 million
Net Margins
-80.42%
Pretax Margin
-80.42%
Return on Equity
N/A
Return on Assets
-188.47%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.23
Quick Ratio
0.10

Sales & Book Value

Annual Sales
$12.06 million
Price / Sales
0.18
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($1.30) per share
Price / Book
-0.08

Miscellaneous

Outstanding Shares
20,235,000
Free Float
22,075,000
Market Cap
$2.12 million
Optionable
No Data
Beta
1.13

Social Links

7 Stocks to Buy And Hold Forever Cover

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:BTCY) was last updated on 8/9/2026 by MarketBeat.com Staff.
From Our Partners